Etoposide
- Generic Name
- Etoposide
- Brand Names
- Etopophos, Toposar, Vepesid
- Drug Type
- Small Molecule
- Chemical Formula
- C29H32O13
- CAS Number
- 33419-42-0
- Unique Ingredient Identifier
- 6PLQ3CP4P3
- Background
A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to ce...
- Indication
For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer
- Associated Therapies
- -
Pembrolizumab After Radiation Therapy and Chemotherapy in Limited Stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-11-20
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT06140407
- Locations
- 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers
- Conditions
- Interventions
- First Posted Date
- 2023-11-15
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 55
- Registration Number
- NCT06132113
- Locations
- 🇧🇪
Brussels - UNIV Saint-Luc, Bruxelles, Belgium
🇺🇸University of Miami, Miami, Florida, United States
🇧🇪Edegem - UNIV UZ Antwerpen, Edegem, Belgium
Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation
- First Posted Date
- 2023-10-31
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT06110572
- Locations
- 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-10-19
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 22
- Registration Number
- NCT06091124
- Locations
- 🇨🇳
Ren Ji Hospital, Shanghai, Shanghai, China
DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-10-11
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 60
- Registration Number
- NCT06077500
- Locations
- 🇪🇸
Hospital Virgen Macarena, Sevilla, Spain
🇧🇪Kortrijk - HOSP AZ Groeninge Kennedylaan, Kortrijk, Belgium
🇫🇷INS Bergonie, Bordeaux, France
Atezolizumab in Large Cell Neuroendocrine Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-09-22
- Last Posted Date
- 2023-09-22
- Target Recruit Count
- 22
- Registration Number
- NCT06049966
- Locations
- 🇬🇷
OCEBER, Athens, Greece
🇬🇷National and Kapodistrian University of Athens, Athens, Greece
Supraphysiological Androgen to Enhance Chemotherapy Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study
- Conditions
- Interventions
- First Posted Date
- 2023-09-15
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 46
- Registration Number
- NCT06039371
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
IN10018 Combination Therapy in Treatment-naïve ES-SCLC
- Conditions
- Interventions
- First Posted Date
- 2023-09-08
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- InxMed (Shanghai) Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT06030258
- Locations
- 🇨🇳
Shandong Province Cancer Hospital, Jinan, China
🇨🇳Tianjin Medical University Cancer Institute & Hospital, Tianjin, China
🇨🇳Henan Provincial People's Hospital, Zhengzhou, China
A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- University of Birmingham
- Target Recruit Count
- 210
- Registration Number
- NCT05991388
- Locations
- 🇬🇧
Bristol Royal Hospital for Children, Bristol, United Kingdom
🇬🇧Royal Manchester Children's Hospital, Manchester, United Kingdom
🇬🇧Birmingham Children's Hospital, Birmingham, United Kingdom
A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia
- First Posted Date
- 2023-07-21
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 70
- Registration Number
- NCT05955261
- Locations
- 🇺🇸
Rady Children's Hospital-San Diego, San Diego, California, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸Cook Children's Medical Center, Fort Worth, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.